Newron Pharmaceuticals S.p.A. (0QOI.L)

CHF 8.22

(0.24%)

Total Debt Summary of Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.'s latest annual total debt in 2023 was 48.41 Million EUR , up 6.03% from previous year.
Newron Pharmaceuticals S.p.A.'s latest quarterly total debt in 2024 Q2 was 48.53 Million EUR , down 0.0% from previous quarter.
Newron Pharmaceuticals S.p.A. reported annual total debt of 45.66 Million EUR in 2022, up 5.99% from previous year.
Newron Pharmaceuticals S.p.A. reported annual total debt of 43.08 Million EUR in 2021, up 63.53% from previous year.
Newron Pharmaceuticals S.p.A. reported quarterly total debt of 48.41 Million EUR for 2023 FY, up 6.03% from previous quarter.
Newron Pharmaceuticals S.p.A. reported quarterly total debt of 47.07 Million EUR for 2023 Q2, down 0.0% from previous quarter.

Annual Total Debt Chart of Newron Pharmaceuticals S.p.A. (2023 - 2005)

Historical Annual Total Debt of Newron Pharmaceuticals S.p.A. (2023 - 2005)

Year	Total Debt	Total Debt Growth
2023	48.41 Million EUR	6.03%
2022	45.66 Million EUR	5.99%
2021	43.08 Million EUR	63.53%
2020	26.34 Million EUR	56.01%
2019	16.88 Million EUR	13409.6%
2018	125 Thousand EUR	0.0%
2017	- EUR	-100.0%
2016	364 Thousand EUR	-49.86%
2015	726 Thousand EUR	-33.21%
2014	1.08 Million EUR	-24.78%
2013	1.44 Million EUR	-19.81%
2012	1.8 Million EUR	-16.46%
2011	2.15 Million EUR	0.0%
2010	- EUR	-100.0%
2009	281 Thousand EUR	-69.09%
2008	909 Thousand EUR	9.12%
2007	833 Thousand EUR	-24.62%
2006	1.1 Million EUR	6.56%
2005	1.03 Million EUR	0.0%

Year	Total Debt	Total Debt Growth
2024 Q2	48.53 Million EUR	0.0%
2023 FY	48.41 Million EUR	6.03%
2023 Q2	47.07 Million EUR	0.0%
2023 Q4	48.41 Million EUR	0.0%
2022 Q2	44.46 Million EUR	0.0%
2022 FY	45.66 Million EUR	5.99%
2022 Q4	45.66 Million EUR	0.0%
2021 Q4	43.08 Million EUR	0.0%
2021 Q2	26.97 Million EUR	0.0%
2021 FY	43.08 Million EUR	63.53%
2020 Q4	26.34 Million EUR	0.0%
2020 FY	26.34 Million EUR	56.01%
2020 Q2	25.41 Million EUR	0.0%
2019 Q2	9.54 Million EUR	0.0%
2019 Q4	16.88 Million EUR	0.0%
2019 FY	16.88 Million EUR	13409.6%
2018 FY	125 Thousand EUR	0.0%
2018 Q2	- EUR	0.0%
2018 Q4	125 Thousand EUR	0.0%
2017 Q4	- EUR	0.0%
2017 FY	- EUR	-100.0%
2017 Q2	182 Thousand EUR	0.0%
2016 Q2	545 Thousand EUR	0.0%
2016 FY	364 Thousand EUR	-49.86%
2016 Q4	364 Thousand EUR	0.0%
2015 Q2	907 Thousand EUR	0.0%
2015 FY	726 Thousand EUR	-33.21%
2015 Q4	726 Thousand EUR	0.0%
2014 Q4	1.08 Million EUR	0.0%
2014 FY	1.08 Million EUR	-24.78%
2014 Q2	1.26 Million EUR	0.0%
2013 Q2	1.62 Million EUR	0.0%
2013 Q4	1.44 Million EUR	0.0%
2013 FY	1.44 Million EUR	-19.81%
2012 Q2	1.98 Million EUR	0.0%
2012 Q4	1.8 Million EUR	0.0%
2012 FY	1.8 Million EUR	-16.46%
2011 Q2	2.15 Million EUR	0.0%
2011 Q4	2.15 Million EUR	0.0%
2011 FY	2.15 Million EUR	0.0%
2010 Q2	281 Thousand EUR	0.0%
2010 Q4	- EUR	0.0%
2010 FY	- EUR	-100.0%
2009 FY	281 Thousand EUR	-69.09%
2009 Q4	281 Thousand EUR	0.0%
2008 FY	909 Thousand EUR	9.12%
2007 FY	833 Thousand EUR	-24.62%
2006 FY	1.1 Million EUR	6.56%
2005 FY	1.03 Million EUR	0.0%

Peer Total Debt Comparison of Newron Pharmaceuticals S.p.A.

Name	Total Debt	Total Debt Difference
Relief Therapeutics Holding AG	4.31 Million CHF	-1023.057%
Tecan Group AG	316.09 Million CHF	84.683%
Santhera Pharmaceuticals Holding AG	25.06 Million CHF	-93.181%
Basilea Pharmaceutica AG	128.6 Million CHF	62.354%
Bachem Holding AG	401 Thousand CHF	-11973.566%
Siegfried Holding AG	525 Million CHF	90.778%
Molecular Partners AG	3.65 Million CHF	-1225.712%